Ragaglitazar

Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

Product Specifications

CAS Number

222834-30-2

Product Name Alternative

(-) -DRF 2725; NNC 61-0029

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ragaglitazar.html

Purity

99.24

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H](OCC)CC1=CC=C(OCCN2C3=C(C=CC=C3)OC4=CC=CC=C24)C=C1

Molecular Formula

C25H25NO5

Molecular Weight

419.47

References & Citations

[1]Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003;140 (3) :527-537. |[2]Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 2004;27 (6) :1324-1329.